Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpox, a viral infection that typically causes flu-like symptoms and skin lesions filled with pus.

A National Institutes of Health (NIH)-funded clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a ...

The World Health Organization has approved the secpond mpox vaccine for emergency use. According to a WHO report released Wednesday, worldwide there have been 115,101 total lab confirmed mpox ...

LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group ...

A National Institutes of Health (NIH)-funded clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a ...

Bavarian Nordic A/S, one of the only companies with a vaccine approved for mpox, has received regulatory approval in Europe for the use of its jab for adolescents.

The US Food and Drug Administration (FDA) granted the vaccine an 'emergency use authorisation' for adolescents during the 2022 global mpox outbreak.

Bavarian Nordic's Jynneos vaccine, also known as Imvanex, is currently only approved for use in adults aged 18 and over.

The vaccine was granted an Emergency Use Authorization for use in adolescents by the FDA during the 2022 global mpox outbreak. For More Such Health News, visit rttnews.com.

Bavarian Nordic shares on Friday surged once again as the mpox vaccine maker says it now is seeking approval to immunize adolescents. Bavarian Nordic is the only U.S. and European-approved vaccine ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

WHO approves Bavarian Nordic's Jynneos vaccine for adolescents aged 12-17 to combat global mpox outbreak.